Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply

Komaki Y.; Yamada A.; Komaki F.; Micic D.; Ido A.; Sakuraba A.

首页> 外文期刊>Alimentary pharmacology & therapeutics. >Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply

【24h】

Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply

机译：编辑：CT-P13，炎症性肠病疾病的抗肿瘤坏死因子 - α代理（英夫利昔单抗） - 作者的回复

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Alimentary pharmacology & therapeutics.》 |2017年第10期|共1页
作者
Komaki Y.; Yamada A.; Komaki F.; Micic D.; Ido A.; Sakuraba A.;
展开▼
作者单位

Univ Chicago Med Sect Gastroenterol Hepatol &

Nutr Dept Med Chicago IL 60637 USA;

Univ Chicago Med Sect Gastroenterol Hepatol &

Nutr Dept Med Chicago IL 60637 USA;

Univ Chicago Med Sect Gastroenterol Hepatol &

Nutr Dept Med Chicago IL 60637 USA;

Northwestern Univ Dept Med Feinberg Sch Med Div Gastroenterol &

Hepatol Chicago IL 60611 USA;

Kagoshima Univ Digest &

Lifestyle Dis Grad Sch Med &

Dent Sci Kagoshima Japan;

Univ Chicago Med Sect Gastroenterol Hepatol &

Nutr Dept Med Chicago IL 60637 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply [J] . Komaki Y., Yamada A., Komaki F., Alimentary pharmacology & therapeutics. . 2017,第10期

机译：编辑：CT-P13，炎症性肠病疾病的抗肿瘤坏死因子 - α代理（英夫利昔单抗） - 作者的回复
2. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease [J] . María Fernanda Guerra Veloz, Federico Argüelles-Arias, Luisa Castro Laria, World Journal of Gastroenterology . 2018,第46期

机译：在炎症性肠病患者中从原来的英夫利昔单抗改用英夫利昔单抗生物仿制药（CT-P13）的疗效和安全性丧失
3. Therapeutic drug monitoring of anti-tumour necrosis factor-alpha agents in inflammatory bowel disease: Limits and improvements [J] . Maria Giraldez-Montero Jose, Gonzalez-Lopez Jaime, Campos-Toimil Manuel, British Journal of Clinical Pharmacology . 2021,第5期

机译：炎症性肠病抗肿瘤坏死因子 - α剂的治疗药物监测：限制与改进
4. Indications for use of infliximab in inflammatory bowel disease [C] . G. ROGLE Falk Symposium . 2007

机译：用于炎症性肠病infliximab的适应症
5. Intracellular Signal Transduction Mechanisms Regulating the Activation of Human Bronchial Epithelial Cells by Interleukin-17A, Interleukin-27, Tumor Necrosis Factor-alpha and Human Basophils in Inflammatory Diseases [D] . Cao, Ju 2010

机译：调节人白细胞介素17A，白细胞介素27，肿瘤坏死因子-α和人类嗜碱性粒细胞在炎性疾病中激活人支气管上皮细胞的细胞内信号转导机制
6. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter observational study in Italian primary inflammatory bowel disease centers [O] . Antonio Tursi, Giammarco Mocci, Roberto Faggiani, 2019

机译：英夫利昔单抗生物仿制药CT-P13在治疗炎症性肠病方面是有效和安全的：在意大利原发性炎症性肠病中心进行的现实多中心观察性研究
7. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases [O] . R. Felwick, J. R. F. Cummings 2017

机译：编辑：CT-P13，炎症性肠病患者（incriximab）的生物仿真性的生物仿真性

相关主题

Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply

著录项

相似文献

相关主题

期刊订阅